Home
Resources
Publications
Structure-based Design of Trifarotene (CD5789), a Potent and Selective RARγ Agonist for the Treatment of Acne

Structure-based Design of Trifarotene (CD5789), a Potent and Selective RARγ Agonist for the Treatment of Acne

Etienne Thoreau, Jean-Marie Arlabosse, Claire Bouix-Peter, Sandrine Chambon, Laurent Chantalat, Sébastien Daver, Laurence Dumais, Gwenaëlle Duvert, Angélique Feret, Gilles Ouvry, Jonathan Pascau, Catherine Raffin, etc.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1736-1741.

PMID: 29706423

Abstract:

Retinoids have a dominant role in topical acne therapy and to date, only RARβ and RARγ dual agonists have reached the market. Given the tissue distribution of RAR isoforms, it was hypothesized that developing RARγ -selective agonists could yield a new generation of topical acne treatments that would increase safety margins while maintaining the robust efficacy of previous drugs. Structural knowledge derived from the X-ray structure of known γ-selective CD437, suggested the design of a novel triaryl series of agonists which was optimized and ultimately led to the discovery of Trifarotene/CD5789.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP125316601	CD437		125316-60-1	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: